Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle

R S Taylor; M F Drummond; G Salkeld; S D Sullivan

doi:10.1136/bmj.329.7472.972

Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle

BMJ. 2004 Oct 23;329(7472):972-5. doi: 10.1136/bmj.329.7472.972.

Authors

R S Taylor¹, M F Drummond, G Salkeld, S D Sullivan

Affiliation

¹ Department of Public Health and Epidemiology, University of Birmingham, Birmingham B15 2TT. r.s.taylor@bham.ac.uk

Abstract

Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to make available for prescription. How do the different approaches work and is it time for standardisation?

Publication types

Review

MeSH terms

Confidentiality
Cost-Benefit Analysis
Drug Approval / economics*
Drug Approval / legislation & jurisprudence
Drug Costs*
Europe
Humans
International Cooperation
Licensure*
Reimbursement Mechanisms
United States